Astrazeneca Plc $AZN Shares Acquired by Cibc World Market Inc.

Cibc World Market Inc. boosted its position in Astrazeneca Plc (NYSE:AZN) by 10.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 71,060 shares of the company’s stock after purchasing an additional 6,639 shares during the period. Cibc World Market Inc.’s holdings in Astrazeneca were worth $12,471,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. TD Asset Management Inc increased its stake in Astrazeneca by 2.1% in the 4th quarter. TD Asset Management Inc now owns 1,112,841 shares of the company’s stock valued at $195,304,000 after purchasing an additional 23,229 shares in the last quarter. Sivia Capital Partners LLC increased its stake in Astrazeneca by 16.6% in the 4th quarter. Sivia Capital Partners LLC now owns 7,996 shares of the company’s stock valued at $1,403,000 after purchasing an additional 1,137 shares in the last quarter. Lido Advisors LLC increased its stake in Astrazeneca by 1.5% in the 4th quarter. Lido Advisors LLC now owns 131,762 shares of the company’s stock valued at $23,124,000 after purchasing an additional 1,985 shares in the last quarter. WCG Wealth Advisors LLC purchased a new position in Astrazeneca during the fourth quarter worth $6,297,000. Finally, GKV Capital Management Co. Inc. purchased a new position in Astrazeneca during the fourth quarter worth $1,580,000. 20.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

AZN has been the subject of several recent research reports. JPMorgan Chase & Co. reissued a “buy” rating on shares of Astrazeneca in a research report on Monday, June 1st. Jefferies Financial Group reiterated a “buy” rating on shares of Astrazeneca in a report on Wednesday, May 13th. Weiss Ratings started coverage on Astrazeneca in a report on Wednesday, March 11th. They issued a “buy (b)” rating for the company. Morgan Stanley reaffirmed an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. Finally, Sanford C. Bernstein reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Monday, May 4th. Twelve research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Astrazeneca presently has a consensus rating of “Moderate Buy” and a consensus target price of $205.33.

Astrazeneca Price Performance

Shares of NYSE:AZN opened at $186.06 on Friday. The company has a market cap of $288.57 billion, a P/E ratio of 27.94, a P/E/G ratio of 1.56 and a beta of 0.25. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. Astrazeneca Plc has a 52 week low of $137.23 and a 52 week high of $212.71. The business has a fifty day simple moving average of $190.84 and a 200-day simple moving average of $184.91.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The business had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. Equities research analysts forecast that Astrazeneca Plc will post 9.52 EPS for the current year.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.